Choosing Among GLP-1 RAs
Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Nurses: 0.25 Nursing contact hour

Released: February 26, 2023

Expiration: February 25, 2025

About This Tool & Disclaimer

Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes

Martin J. Abrahamson, MD, FACP; Zachary T. Bloomgarden, MD, MACE; Anne Peters, MD; Richard E. Pratley, MD; and Robert Zimmerman, MD, provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in February 2020 and reflects the opinions of the expert panel at that time.

The goal of the tool is to educate clinicians on making optimal management choices when selecting among GLP-1 RAs.

A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include cardiovascular disease, renal function, A1C level, retinopathy, and the need for weight loss. It should be realized that these are not exclusive characteristics when making management choices for patients with T2D. Other considerations that are not included in this tool, such as the presence of various comorbidities, should also be considered, when appropriate.

This tool assumes that the patient is an adult diagnosed with T2D and has not achieved his/her target A1C goal despite 3 months of treatment with metformin.

It also assumes that the patient has no contraindications to GLP-1 RAs, including no unexplained pancreatitis, no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and that the patient is not pregnant.

Based on the characteristics entered, the tool will display experts’ recommendations for that specific patient case.

This program is supported by an educational grant from Novo Nordisk.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Martin J. Abrahamson, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca and Novo Nordisk.

Zachary T. Bloomgarden, MD, MACE, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Merck, Novartis, and Sanofi and has ownership interest in Humana, Johnson & Johnson, and Novartis.

Anne Peters, MD, has disclosed that she has received consulting fees from Abbott Diabetes Care, Boehringer Ingelheim, Lilly, Livongo, MannKind, Merck, Novo Nordisk, Pendulum Therapeutics, and Sanofi; has received funds for research support from Dexcom and vTv Therapeutics; and has ownership interest in Livongo, Mellitus Health, Omada Health, Pendulum Therapeutics, and Stability Health.

Richard E. Pratley, MD has disclosed that he has received funds for research support paid to his institution from Lexicon, Ligand, Lilly, Merck, Novo Nordisk, and Sanofi; consulting fees from GlaxoSmithKline, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi; and fees for non-CME/CE services paid to his institution from Novo Nordisk.

Robert Zimmerman, MD, has disclosed that he has received consulting fees from Novo Nordisk; fees for non-CME/CE services from LifeScan and Merck; and funds for research support from Bayer, Merck, and Novo Nordisk.

© 2020 Clinical Care Options, LLC. All rights reserved.

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices when selecting among GLP-1 RAs. The information provided is based on expert guidance of Martin J. Abrahamson, MD, FACP; Zachary T. Bloomgarden, MD, MACE; Anne Peters, MD; Richard E. Pratley, MD; and Robert Zimmerman, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2020 Clinical Care Options, LLC. All rights reserved.

Program Content